Roquefort Therapeutics (LON:COIL) Shares Down 2.1% – What’s Next?

Roquefort Therapeutics plc (LON:COIL)’s share price dropped 2.1% during trading on Tuesday . The stock traded as low as GBX 9.30 and last traded at GBX 9.30. Approximately 22,609 shares were traded during trading, a decline of 92% from the average session volume of 298,991 shares. The stock had previously closed at GBX 9.50.

Roquefort Therapeutics Stock Up 5.3%

The firm has a market cap of £42.68 million, a price-to-earnings ratio of -0.46 and a beta of 0.05. The firm has a 50 day moving average of GBX 9.57 and a 200 day moving average of GBX 10.57. The company has a quick ratio of 3.07, a current ratio of 2.80 and a debt-to-equity ratio of 8.07.

Roquefort Therapeutics (LON:COIL) last announced its quarterly earnings data on Wednesday, May 6th. The company reported GBX (2.19) EPS for the quarter. Roquefort Therapeutics had a negative return on equity of 18.30% and a negative net margin of 57,057.07%.

Roquefort Therapeutics Company Profile

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.